Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years

被引：0

作者：

Cappellini, M. Domenica ^{[1
]}

Perrotta, Silverio ^{[2
]}

Agaoglu, Leyla ^{[3
]}

Aydinok, Yesim ^{[4
]}

Capra, Marcello ^{[5
]}

Canatan, Duran ^{[6
]}

Drelichman, Guillermo ^{[7
]}

Kilinc, Yurdanur ^{[8
]}

Magnano, Carmelo ^{[9
]}

Porter, John B. ^{[10
]}

Piga, Antonio ^{[11
]}

Griffel, Louis ^{[12
]}

Lagrone, Darlene ^{[12
]}

Clark, Joan ^{[13
]}

Kattamis, Antonis ^{[14
]}

机构：

[1] Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Milan, Italy

[2] I Policlin II Univ Napoli, Naples, Italy

[3] Istanbul Univ, Istanbul Sch Med, Div Pediat Hematol Oncol, Istanbul, Turkey

[4] Ege Univ, Fac Med, Izmir, Turkey

[5] Osped Civ & Benefratelli G Di Cristina M Ascoli, Palermo, Italy

[6] Suleyman Demirel Univ, Fac Med, TR-32200 Isparta, Turkey

[7] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina

[8] Cukurova Univ, Fac Med, Dept Pediat Hem Onc, Adana, Turkey

[9] Az Osped Riliervo Nazl & Alta Spec Garibaldi, Catania, Italy

[10] UCL, London, England

[11] Univ Turin, Turin, Italy

[12] Novartis Pharmaceut, E Hanover, NJ USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Univ Athens, Dept Pediat 1, Athens, Greece

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1558 / 1559

页数：2

共 50 条

[31] Impact Of Liver Iron Overload On Myocardial T2*Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years
Porter, John
Taher, Ali T.
Aydinok, Yesim
Cappellini, Maria D.
Kattamis, Antonis
El-Ali, Ali
Martin, Nicolas
Pennell, Dudley
BLOOD, 2013, 122 (21)
[32] Plasma LPI in β-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670).
Daar, S
Taher, A
Pathare, A
Krahn, U
Gathmann, I
Nick, H
Hadler, D
BLOOD, 2005, 106 (11) : 758A - 758A
[33] Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
Falahati, Vahid
Ghasemi, Ali
Safari, Mohammad Reza
Ghaffari, Kazem
Yousefichaijan, Parsa
Zamanian, Maryam
ADVANCED BIOMEDICAL RESEARCH, 2022, 11 (01): : 84
[34] Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden
Taber, Ali
Al Jefri, Abdullah
Elalfy, Mollsen Saleh
Al Zir, Kusai
Daar, Shahina
Damanhouri, Ghazi
Kriemler-Krahn, Ulrike
Pfluger, Dietrich
Hadler, Dominik
El-Beshlawy, Aural
BLOOD, 2007, 110 (11) : 817A - 817A
[35] LONG-TERM EFFICACY OF DEFERASIROX FOR CARDIAC SIDEROSIS IN THALASSEMIA MAJOR
Casale, M.
Citarella, S.
Palmieri, F.
Lo Mastro, M.
Pugliese, U.
Amendola, G.
De Michele, E.
Ragozzino, A.
Tartaglione, I.
Della Rocca, F.
Nobili, B.
Perrotta, S.
HAEMATOLOGICA, 2013, 98 : 701 - 701
[36] Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy
不详
BLOOD, 2009, 114 (22) : 1556 - 1557
[37] Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia
Haghpanah, Sezaneh
Zarei, Tahereh
Zahedi, Zohreh
Karimi, Mehran
HEMATOLOGY, 2014, 19 (04) : 187 - 191
[38] Efficacy and safety of deferasirox for reducing total body and cardiac iron in Thalassemia
Rashid Merchant
Javed Ahmed
Pradeep Krishnan
Bhavin Jankharia
Indian Pediatrics, 2012, 49 : 281 - 285
[39] Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India
Parakh, Nupur
Chandra, Jagdish
Sharma, Sunita
Dhingra, Bhavna
Jain, Rajesh
Mahto, DeoNath
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (03) : 209 - 213
[40] Efficacy and Safety of Deferasirox for Reducing Total Body and Cardiac Iron in Thalassemia
Merchant, Rashid
Ahmed, Javed
Krishnan, Pradeep
Jankharia, Bhavin
INDIAN PEDIATRICS, 2012, 49 (04) : 281 - 285

← 1 2 3 4 5 →